Charles River Laboratories International, Inc. — FY2014 Form 10-K
Reporting period: Fiscal year ended December 27, 2014; fiscal Q4 ended the same date. This is an annual filing, with selected quarterly results included. Amounts are in U.S. dollars; financial figures are in millions unless stated otherwise.
Business context
Charles River is an early-stage contract research organization supporting drug discovery and preclinical development, alongside research models and manufacturing-support products and services. It reported three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support. The company operated approximately 60 facilities in 17 countries. No commercial client represented more than 5% of annual revenue; strategic relationships accounted for more than 25%.
Financial performance
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $1,297.7 | $1,165.5 |
| Operating income | $177.7 | $151.4 |
| Income from continuing operations | $129.9 | $105.4 |
| Net income attributable to common shareholders | $126.7 | $102.8 |
| Diluted EPS from continuing operations | $2.70 | $2.15 |
| Operating cash flow | $252.1 | $209.0 |
| Capital expenditures | $56.9 | $39.2 |
- Revenue increased 11.3%; management attributed approximately $71.4 million of DSA growth to the Argenta and BioFocus acquisition. Foreign currency translation reduced reported revenue by $1.7 million.
- Calculated operating margin was 13.7%, versus 13.0% in FY2013; calculated net margin attributable to common shareholders was 9.8%, versus 8.8%. Cost of revenue fell to 63.6% of revenue from 66.1%, while SG&A rose to 20.7% from 19.4%.
- Calculated operating cash flow less capital expenditures was $195.2 million, compared with $169.9 million in FY2013. Investing activities used $298.0 million, principally for acquisitions.
- At year-end, cash and cash equivalents were $160.0 million, with an additional $16.2 million in time deposits. Working capital was $310.7 million; total current assets were $606.9 million and current liabilities $296.2 million.
- Debt was $753.8 million; total debt and capital lease obligations were $777.9 million. The weighted-average debt rate was 1.42%, and borrowings were primarily floating-rate. A 100-basis-point rate increase was estimated to raise annual pretax interest expense by about $9.3 million. The company reported compliance with debt covenants.
Segments and Q4 results
- FY2014 segment revenue: RMS $507.3 million (down 0.8%); DSA $538.2 million (up 24.5%); Manufacturing $252.1 million (up 13.7%). Segment operating income was $121.4 million, $69.7 million, and $78.6 million, respectively, before $92.1 million of unallocated corporate overhead.
- Q4 revenue was $329.5 million, versus $289.2 million in Q4 2013. Operating income was $40.8 million versus $24.6 million; continuing-operations income was $28.5 million versus $19.5 million. Diluted EPS from continuing operations was $0.59 versus $0.40.
Material changes, outlook, and risks
- FY2014 growth reflected improved demand for discovery and safety assessment, particularly from mid-tier clients, and broad-based manufacturing growth. Management said safety-assessment utilization was approaching optimal levels and price trends were stable to slightly improving. Research-model demand remained constrained.
- The company acquired Argenta and BioFocus, VivoPath, and ChanTest to expand discovery capabilities. Argenta and BioFocus contributed $71.4 million in FY2014 revenue but $1.8 million in operating income. Amortization expense rose to $26.0 million from $17.8 million, and acquisition evaluation/integration costs and higher SG&A also weighed on results.
- Management stated that existing funds, operating cash flow, and financing access should be sufficient for foreseeable operating needs. The filing provides no quantified FY2015 revenue or earnings guidance. It describes strategic outsourcing and client pipeline investment as potential growth drivers, while noting uncertainty in research budgets and demand.
- FY2014 included $7.8 million of severance and retention expense and facility consolidation charges, including $2.2 million of impairments and other charges and $4.3 million of accelerated depreciation. Goodwill impairment tests found no impairment; reported asset impairment charges were small.
- The company reserved $1.5 million for excess billings on certain government contracts dating back to 2007. The investigation found the issue at two RMS facilities; the company could not estimate potential losses beyond the reserve and was cooperating with government agencies. Separately, the National Cancer Institute canceled a contract that had generated $10–$11 million annually; management expected to retain approximately half through direct sales.
- Other risks include client cancellation or reductions in contract scope, reliance on pharmaceutical R&D and government funding, animal contamination and regulatory compliance, competition and alternative research technologies, foreign exchange, tax disputes, acquisition integration, and pension obligations. A prior Phase I clinical business divestiture continued to generate discontinued-operation losses; remaining lease payments were $10.0 million.
Important facts for investors to verify
- How much of DSA growth and margin improvement is sustainable organically, separate from acquisitions and currency effects.
- Progress integrating Argenta and BioFocus, VivoPath, and ChanTest, including purchase-price adjustments, contingent payments, and realized returns.
- Resolution and potential financial exposure from the government-contract billing investigation, and the expected impact of the canceled NCI contract.
- Debt reduction capacity and sensitivity to floating interest rates, alongside planned capital spending, repurchases, and acquisition commitments.
- Developments in Canadian and other tax audits, research tax credits, and the $34.6 million liability for uncertain tax positions.
- Whether backlog translates into revenue: year-end backlog was $115.7 million in RMS, $310.5 million in DSA, and $27.5 million in Manufacturing; the company cautioned that backlog may be delayed, changed, or canceled.